Summary
Antibody responses to individual structural proteins (E1, E2, and C) of the M33 wild rubella virus and the RA 27/3 live attenuated rubella strain were assayed by immunoblotting in 11 girls, following immunization with RA 27/3 rubella vaccine. Serum samples were drawn before immunization and at 10 days, 1 month, 1 year, 2 years, and 3 years afterwards. All the subjects showed antibodies to E1 glycoprotein of both the virus strains up to three years after immunization, indicating the importance of E1 in immunity. Antibodies to E1 were always present when with neutralizing activity was observed. Antibodies to E2 protein of both the viruses and to the C protein of the M33 virus gradually disappeared with time in some samples, while antibodies to C protein of the RA 27/3 virus strain were found persistently in all the sera.
Similar content being viewed by others
References
Steward MW, Howard CR (1987) Synthetic peptides: a next generation of vaccines. Immunol Today 8: 51–58
Warren KS (1986) New scientific opportunities and old obstacles in vaccine development. Proc Natl Acad Sci USA 83: 9275–9277
Norrby E (1987) Prospects for new viral vaccines. Microbiol Sci 4: 202–205
Balfour HH Jr, Amren DP (1978) Rubella, measles and mumps antibodies following vaccination of children: a potential rubella problem. Am J Dis Child 132: 573–577
O'Shea S, Parsons G, Best JM, Banatvala JE, Balfour HH Jr (1981) How well do low levels of rubella antibody protect? Lancet ii: 1284
Tingle AJ, Yang T, Allen M, Kettyls GD, Larke RPB, Schulzer M (1983) Prospective immunological assessment of arthritis induced by rubella vaccine. Infect Immun 40: 22–28
Tingle AJ, Chantler JK, Kettyls GD, Larke RPB, Schulzer M (1985) Failed rubella immunization in adults: association with immunologic and virological abnormalities. J Infect Dis 151: 330–336
Waxham NM, Wolinsky JS (1985) A model of the structural organization of rubella virions. Rev Infect Dis 7 [Suppl 1]: S 133–139
Dorsett PH, Miller DC, Green KY (1985) Structure and function of the rubella virus proteins. Rev Infect Dis 7 [Suppl 1]: S 150–156
Pettersson RF, Oker-Blom C, Kalkkinen N, Kallio A, Ulmanen I, Kääriäinen L, Partanen P, Vaheri A (1985) Molecular and antigenic characteristics and synthesis of rubella virus structural proteins. Rev Infect Dis 7 [Suppl 1]: 140–149
Green KY, Dorsett PH (1986) Rubella virus antigens: localization of epitopes involved in hemagglutination and neutralization by using monoclonal antibodies. J Virol 57: 893–898
Trudel M, Nadon F, Séguin C, Amarouch A, Payment P, Gillam S (1985) El glycoprotein of rubella virus carries an epitope that binds a neutralizing antibody. J Virol Methods 12: 243–250
Loo TW, MacDonald I, Clarke DM, Trudel M, Tingle A, Gillam S (1986) Detection of antibodies to individual proteins of rubella virus. J Virol Methods 13: 149–159
Ho-Terry L, Cohen A (1980) Degradation of rubella virus envelope components. Arch Virol 65: 1–13
Forsgren M, Carlström G, Strangert K (1979) Congenital rubella after maternal reinfection. Scand J Infect Dis 11: 81–83
Partridge JW, Flewett TH, Whitehead JEM (1981) Congenital rubella affecting an infant whose mother had rubella antibodies before conception. Br Med J 282: 187–188
Cusi MG, Rossolini GM, Cellesi C, Valensin PE (1988) Antibody response to wild rubella virus structural proteins following immunization with RA 27/3 live attenuated vaccine. Arch Virol 101: 25–33
Cellesi C, Bianchi Bandinelli ML, Cusi MG, Di Cairano ML, Valensin PE, Barberi A, Rossolini A (1985) Rubella in teenagers: epidemiology and prophylaxis in Siena, Italy. J Biol Stand 13: 283–293
Schluederberg A, Horstmann DM, Andiman WA, Randolph MF (1978) Neutralizing and hemagglutination-inhibition antibodies to rubella virus as indicators of protective immunity in vaccinees and naturally immune individuals. J Infect Dis 138: 877–883
Reed LJ, Muench H (1938) A simple method of estimating fifty per cent endpoints. Am J Hyg 27: 493–495
Horstmann DM, Schluederberg A, Emmons JE, Evans BK, Randolph MF, Andiman WA (1985) Persistence of vaccine-induced immune responses to rubella: comparison with natural infection. Rev Infect Dis 7 [Suppl 1]: S80–85
Plotkin SA, Farquhar JD, Ogra PL (1973) Immunologic properties of RA 27/3 rubella virus vaccine. A comparison with strains presently licensed in the United States. JAMA 225: 585–590
Valensin PE, Rossolini GM, Cusi MG, Zanchi A, Cellesi C, Rossolini A (1987) Specific antibody patterns over a two-year period after rubella immunization with RA 27/3 live attenuated vaccine. Vaccine 5: 289–294
Waxham MN, Wolinsky JS (1985) Detailed immunologic analysis of the structural polypeptides of rubella virus using monoclonal antibodies. Virology 143: 153–165
Umino Y, Sato TA, Katow S, Matsuno T, Sugiura A (1985) Monoclonal antibodies directed to E1 glycoprotein of rubella virus. Arch Virol 83: 33–42
Tingle AJ, Chantler JK, Pot KH, Paty DW, Ford DK (1985) Postpartum rubella immunization: association with development of prolonged arthritis, neurological sequelae, and chronic rubella viremia. J Infect Dis 152: 606–612
Chantler JK, Ford DK, Tingle AJ (1981) Rubella-associated arthritis: rescue of rubella virus from peripheral blood lymphocytes two years postvaccination. Infect Immunol 32: 1274–1280
Preblud SR, Stetler HC, Frank JA, Greaves WL, Hinman AR, Herrmann KL (1981) Fetal risk associated with rubella vaccine. JAMA 246: 1413–1417
O'Shea S, Best JM, Banatvala JE (1983) Viremia, virus excretion, and antibody responses after challenge in volunteers with low levels of antibody to rubella virus. J Infect Dis 148: 639–647
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cusi, M.G., Metelli, R. & Valensin, P.E. Immune responses to wild and vaccine rubella viruses after rubella vaccination. Archives of Virology 106, 63–72 (1989). https://doi.org/10.1007/BF01311038
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01311038